Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti‐β7 integrin therapy for inflammatory bowel disease

BACKGROUND: Novel treatments with superior benefit‐risk profiles are needed to improve the long‐term prognosis of patients with inflammatory bowel disease (IBD). Etrolizumab—a monoclonal antibody that specifically targets β7 integrins—is currently under phase III clinical evaluation in IBD. AIM: Thi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Aliment Pharmacol Ther
Hauptverfasser: Tang, M. T., Keir, M. E., Erickson, R., Stefanich, E. G., Fuh, F. K., Ramirez‐Montagut, T., McBride, J. M., Danilenko, D. M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Review Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6001693/
https://ncbi.nlm.nih.gov/pubmed/29601644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14631
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge